28,388 trials (keyword fallback)
Bacterial Infection
Primary: Number of Participants With at Least One Grade 2 (Moderate) or Higher Treatment-emergent Adverse Event — 1; 0; 0; 1 Participants
Pharmacokinetics of Avycaz in ICU Patients
Primary: Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Volume of Distribution Parameter in Intensive Care Patients — 34 Liter
Critical Illness
Primary: Vital Status at Hospital Discharge — 1232; 165 participants
Covid19 and Mortality
Primary: Acute Physiology and Chronic Health Evaluation II Score — 13.1; 18.3 score on a scale
Stroke · Ischemic Stroke
Primary: Number of Participants Needing ICU Care/Interventions Within the First 24 Hours of IV tPA Administration — 0 Participants
Delirium · Impaired Cognition · Long Term Psychologic Disorders
Primary: Delirium/Coma-free Days (DCFDs) — 8; 8; 7 days
Critical Illness · Communication Disabilities
Primary: Change in Peritraumatic Distress Inventory — 14.6; 14.2; 13.0; 14.4 score on a scale
Intensive Care Unit Syndrome · Intensive Care Neurological Disorder · Intensive Care (ICU) Myopathy
Primary: Number of Components of the ICU Recovery Program Received — 2; 1 interventions
Pneumonia, Ventilator-Associated
Primary: Incidence of Ventilator-Associated Pneumonia (VAP) — 16; 27 Participants
Delirium
Primary: Days Without Delirium — 2.54; 3.38 delirium free days — p=0.22
Intensive Care Unit Syndrome
Primary: Feasibility of Bundle Delivery — 50 Participants
Delirium · Alzheimer Disease
Primary: Cognitive Status Outcome at 6 Months — 0.24; 0.36; 0.21; 0.35 Z-score — p=0.747
Critically Ill · Hemodialysis
Primary: Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis — 6.3 mL/min
Critical Illness
Primary: Hypothetical Recruitment Rate for a Future Randomised Controlled Trial. — 30 Participants
Respiratory Failure
Primary: Number of Participants With Plasma 25(OH)D Concentration >30ng/mL at Baseline — 2; 2; 1 participants